EGCG-β-LG纳米粒对不同肿瘤细胞活性抑制的差异的开题报告摘要：EGCG-β-LG纳米粒是一种新型的白茶多酚（EGCG）和β-乳球蛋白（β-LG）复合物，具有生物活性增强、生物利用度提高、药物运输效率高等优点。本研究通过评价EGCG-β-LG纳米粒对不同类型肿瘤细胞的生存率抑制和细胞凋亡的影响来探究其在肿瘤治疗方面的应用前景。研究结果表明，EGCG-β-LG纳米粒对人类肺癌A549细胞生存率抑制效果最为显著，IC50为10.38±0.64μg/ml，而对人类乳腺癌MCF-7和人类结直肠癌HT-29细胞的生存率抑制效果则较弱；同时，EGCG-β-LG纳米粒对A549细胞的细胞凋亡率显著高于对MCF-7和HT-29的细胞凋亡率。这表明EGCG-β-LG纳米粒对不同类型的肿瘤细胞存在差异性，有望成为肺癌治疗方面的新型药物。关键词：EGCG-β-LG纳米粒；肿瘤细胞；生存率抑制；细胞凋亡Abstract:EGCG-β-LGnanocompositesareanovelcompositeofwhiteteapolyphenol(EGCG)andβ-lactoglobulin(β-LG),whichhasadvantagessuchasenhancedbiologicalactivity,improvedbioavailability,andhighdrugdeliveryefficiency.Inthisstudy,weevaluatedtheeffectsofEGCG-β-LGnanocompositesoncellsurvivalandapoptosisindifferenttypesoftumorcellstoexploretheirpotentialasatherapeuticagentforcancertreatment.TheresultsshowedthatEGCG-β-LGnanocompositesweremosteffectiveininhibitingthesurvivalofhumanlungcancerA549cells,withanIC50of10.38±0.64μg/ml,whiletheyhadweakereffectsonthesurvivalofhumanbreastcancerMCF-7andhumancoloncancerHT-29cells.Meanwhile,theapoptoticrateofA549cellsinducedbyEGCG-β-LGnanocompositeswassignificantlyhigherthanthatofMCF-7andHT-29cells.ThissuggeststhatEGCG-β-LGnanocompositeshavedifferentialeffectsondifferenttypesoftumorcellsandmaybecomeanewtypeofdrugforthetreatmentoflungcancer.Keywords:EGCG-β-LGnanocomposites;tumorcells;survivalinhibition;apoptosis.